Combination therapy to enhance the anticancer efficacy of platinum drugs
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsWei Qian, Peter Wipf, Bennett Van Houten
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death. It is based, at least in part, on the discovery that in platinum drug-resistant cell lines, certain compounds, together with a second antiproliferative agent (e.g., cisplatin), act synergistically to promote apoptosis. Accordingly, the present invention provides for novel anticancer strategies.
Claims35
A method for reducing cancer cell proliferation and/or promoting cancer cell death by administering, to a cancer cell, an effective amount of a compound having a formula selected from the group consisting of Formula I:
- wherein G is C;
- Q is C;
- and R is selected from H, a substituted or unsubstituted alkyl, a fluorinated or partially fluorinated alkyl, a halogen, cyano, azido, hydroxyl, a substituted or unsubstituted sulfonyl;
A method for reducing cancer cell proliferation and/or promoting cancer cell death in a subject in need of such treatment comprising administering, to the subject, an effective amount of a compound having a formula selected from the group consisting of Formula I:
- wherein G is C;
- Q is C;
- and R is selected from H, a substituted or unsubstituted alkyl, a fluorinated or partially fluorinated alkyl, a halogen, cyano, azido, hydroxyl, a substituted or unsubstituted sulfonyl;
A pharmaceutical formulation comprising an effective amount of a compound for reducing cancer cell proliferation and/or promoting cancer cell death, having a formula selected from the group consisting of Formula I:
- wherein G is C;
- Q is C;
- and R is selected from H, a substituted or unsubstituted alkyl, a fluorinated or partially fluorinated alkyl, a halogen, cyano, azido, hydroxyl, a substituted or unsubstituted sulfonyl;
- and a pharmaceutically acceptable buffer.
A kit comprising a container comprising an effective amount of a compound for reducing cancer cell proliferation and/or promoting cancer cell death, having a formula selected from the group consisting of Formula I:
- wherein G is C;
- Q is C;
- and R is selected from H, a substituted or unsubstituted alkyl, a fluorinated or partially fluorinated alkyl, a halogen, cyano, azido, hydroxyl, a substituted or unsubstituted sulfonyl;
- and a pharmaceutically acceptable buffer.
Dependencies are inferred from the claim text.